In Brief
Different viral antigens are required to initiate and then to drive the selection of HIV broadly neutralizing antibodies, showing that vaccination to induce HIV protection in humans will likely require immunization with a succession of related immunogens.
SUMMARY
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs) that can prevent infection, but it has not yet been possible to elicit these antibodies by immunization. To systematically explore how immunization might be tailored to produce them, we generated mice expressing the predicted germline or mature heavy chains of a potent bNAb to the CD4 binding site (CD4bs) on the HIV-1 envelope glycoprotein (Env). Immunogens specifically designed to activate B cells bearing germline antibodies are required to initiate immune responses, but they do not elicit bNAbs. In contrast, native-like Env trimers fail to activate B cells expressing germline antibodies but elicit bNAbs by selecting for a restricted group of light chains bearing specific somatic mutations that enhance neutralizing activity. The data suggest that vaccination to elicit anti-HIV-1 antibodies will require immunization with a succession of related immunogens.
INTRODUCTION
A fraction of HIV-1-infected individuals develop potent broadly neutralizing antibodies (bNAbs) that target several independent sites on gp160, the viral envelope glycoprotein (Env) . When passively transferred into non-human primates or into genetically engineered or humanized mice, these antibodies can protect against challenge with chimeric simian/ human immunodeficiency virus (SHIV) or HIV-1 viruses, respectively (Burton et al., 2012; Klein et al., 2013; Mascola and Haynes, 2013; West et al., 2014) . Antibodies were also the only correlate of protection in a recent phase 3 human HIV-1 vaccine trial that showed limited efficacy (Karasavvas et al., 2012; Rerks-Ngarm et al., 2009) . Thus, one of the goals of the HIV-1 vaccine effort has been to elicit bNAbs by immunization. However, this goal has not been achieved despite more than 25 years of concerted vaccination efforts.
Why it is so difficult to elicit these antibodies was only fully appreciated after the advent of single-cell antibody cloning techniques (Klein et al., 2013; West et al., 2014) . Antibody cloning revealed that anti-HIV-1 antibodies are unusual in that they carry large numbers of somatic hypermutations that are required for binding to most recombinant HIV-1 Env antigens and for broad neutralization (Mouquet et al., 2010; Scheid et al., 2011; Wu et al., 2010) . These mutations are likely to arise as a result of multiple rounds of hypermutation and selection in the germinal center in response to rapidly evolving escape mutations in the HIV-1 Env (Mouquet et al., 2010; Scheid et al., 2009 ). This idea is supported by the observation that bNAbs co-evolve with HIV-1 in the host through multiple rounds of HIV-1 escape from antibody pressure (Doria-Rose et al., 2014; Klein et al., 2013; Liao et al., 2013; Wu et al., 2015) . Considered together, these findings have led to the hypothesis that eliciting such antibodies may require using a series of engineered or naturally arising antigens to direct the antibody response (Dimitrov, 2010; Doria-Rose et al., 2014; Jardine et al., 2013; Klein et al., 2013; Liao et al., 2013; Wu et al., 2011) . According to this idea, an antigen that activates B cells carrying a germline antibody would initially be used to expand a reactive B cell clone and produce a group of somatic variants by hypermutation. To shepherd the antibody response toward broad neutralization, the initial immunization would be followed by one or a series of related antigens.
To test this hypothesis, we produced immunoglobulin (Ig) heavy-chain knockin mice expressing the predicted germline (GLV H ) or mature mutated (MuV H ) version of 3BNC60, a bNAb that targets the CD4 binding site (CD4bs) of HIV-1 (Scheid et al., 2011) . 3BNC60 is one of a closely related group of potent antibodies referred to as VRC01-class antibodies (West et al., 2012) , arising in several different individuals, all of which are derived from IgHV1-2*02 . In addition to the shared origin of their heavy chains, this group of antibodies all carry light chains that have short (five amino acid [aa]) third complementarity determining regions (CDR3s) (West et al., 2012; Zhou et al., 2013) .
Mice that carry heavy-chain knockin genes have a restricted B cell repertoire because the heavy chain is fixed. Nevertheless, the repertoire remains relatively diverse because the antibody light chain is produced by random VJ recombination in developing B cells. Thus, only a small fraction of the B cells carry heavy and light chains that combine to produce antibodies able to bind to the HIV-1 Env (see below). Immunization of GLV H mice affords the opportunity to evaluate antigens for their ability to select B cells expressing light chains that show features that could support bNAb evolution. In contrast, MuV H mice represent a synthetic intermediate because the human heavy chain carries all of the required mutations, but the mouse light chain is germline.
To track the evolution of the HIV-1 antibody response in GLV H and MuV H mice, we immunized them with antigens designed to bind to the predicted unmutated precursor of 3BNC60 or with BG505 SOSIP trimers that resemble the native HIV-1 Env.
RESULTS

3BNC60
Knockin Mice GLV H and MuV H mice were produced by gene targeting using C57Bl-6 embryonic stem cells (Pelanda et al., 1997; Shih et al., 2002) (Figure S1A) . GLV H reverts all of the heavy chain residues outside of CDRH3 (Hoot et al., 2013) to germline. CDRH3 cannot be reverted with certainty because the sequence represents the combined effects of random V(D)J recombination, N addition, deletion, and somatic mutation. Both strains showed near-normal frequencies of immature and recirculating B cells in the BM (Figure S1B ) and of mature B cell populations in spleen ( Figure S1C ).
To determine the frequency of naive B cells that bind to Envbased antigens in the knockin mice, we stained splenocytes with an improved version (eOD-GT8) of the previously described immunogen eOD-GT6, an engineered outer domain of gp120 designed to bind to both germline and mature versions of 3BNC60 and other VRC01-class antibodies (see below and Jardine et al., 2013; Jardine et al., 2015) . The average number of naive B cells that bind to eOD-GT8 in GLV H and MuV H mice (0.08% and 0.13%, respectively) was similar to that found in wild-type C57Bl6 mice (0.05%), indicating that these cells are rare and found at frequencies similar to those in wild-type C57Bl6 mice ( Figures  1A and 1B) . To examine the antibody repertoire in naive B cells in these mice, we isolated single cells by flow cytometry and sequenced their Ig genes. As expected, the heavy chain was always the product of the respective knockin allele, and the mouse light-chain sequences were less diverse than in wild-type C57Bl6 B cells (51/59, 24/44, and 33/63 unique sequences for wild-type C57Bl6, GLV H , and MuV H , respectively) ( Figure 1C) . Consistent with the rare occurrence of antigen-binding cells in the naive knockin mice ( Figures 1A and 1B) , none of the mouse light chains showed the five-residue CDRL3 signature typical of authentic 3BNC60 or of other VRC01-class antibodies ( Figure 1D ).
Immune Responses in 3BNC60 GLV H Knockin Mice
Like most other potent bNAbs, reversion of the somatic mutations in the 3BNC60 antibody to the predicted germline antibody results in complete loss of affinity and neutralizing activity for all recombinant HIV-1 Env proteins and viruses tested (Hoot et al., 2013; Jardine et al., 2013; McGuire et al., 2013; Mouquet et al., 2010; Scheid et al., 2011; Xiao et al., 2009) (Figures S2A and  S2B ). To determine whether naive GLV H B cells can be stimulated with antigens that are specifically engineered to activate cells expressing germline VRC01-class antibodies ( Figure S2C ), we immunized these mice and wild-type C57Bl6 controls with eOD-GT8 60-mer or with multimerized 426c.TM 4 DV1-3 (McGuire et al., 2014; Experimental Procedures) . Immunization produced a robust antibody response in wild-type C57Bl6 and GLV H mice after one or two immunizations (Figures 2A, 2B , and S3A, and S3B). Although the response was not restricted to the CD4bs, as determined by ELISA, sera from the eOD-GT8 60-mer-immunized mice showed some preference for the wild-type versus a control eOD-GT8 CD4bs knockout protein (Figures 2A and S3A) . Finally, none of the sera from the eOD-GT8 60-mer-immunized mice showed cross-reactivity to a native-like BG505 SOSIP Sanders et al., 2013) or a YU2 gp140 foldon trimer (YU2 gp140-F) (Yang et al., 2002) (Figures 2C and S3C) . eOD-GT8-binding IgG + B cells are rare in GLV H naive mice but increase to 5.8% on average after immunization ( Figure S3D ). A fraction of these cells appeared to express CD4bs-specific antibodies as measured by flow cytometry ( Figure S3E ). To further characterize the B cell responses to eOD-GT8 60-mer in GLV H mice, we sorted single cells that bound to eOD-GT8, but not eOD-GT8 CD4bs knockout, and cloned their antibody genes ( Figure S3E ). 71 light-and 55 heavy-chain sequences were obtained from 4 mice. As expected, all of the heavy chains were GLV H . The 71 antibodies include 8 clones ranging in size from 2 to 13 clonal members, one of which appeared in more than one mouse. In addition, there were 13 cells that carried unique sequences ( Figures 2D and S3F and Table S1A ). The CDRL3 lengths of the light chains showed a near-normal distribution when compared to naive GLV H or control wild-type C57Bl6 mice, with only one of the expanded clones showing the five-residue CDRL3 signature typical of 3BNC60 and related antibodies (Figures 2E and S3G and Table S1A ). Out of 20 antibodies cloned from B cells expressing antibodies that bound to eOD-GT8 but not eOD-GT8 CD4bs knockout by FACS, 7 were CD4bs specific as measured by ELISA (Figure 2F) . However, none of the 17 monoclonal antibodies tested neutralized any of the tier 1 and 2 viruses tested (Table S1B) . We conclude that the eOD-GT8 60-mer, an antigen designed to activate B cells expressing germline 3BNC60 antibody and select only for early somatic mutations, elicits B cell responses in mice that carry germline knockin antibody heavy chains, including B cells expressing antibody light chains with five-residue CDRL3s, but these antibodies do not neutralize HIV-1.
To determine whether GLV H B cells can respond to a more native-appearing HIV-1 antigen in vivo, we immunized these mice and wild-type C57Bl6 mice with BG505 SOSIP Sanders et al., 2013) or YU2 SOSIP. Wild-type C57Bl6 mice developed detectable antibody responses as measured by ELISA. In contrast, GLV H mice failed to respond to these antigens (Figures 2G and S3H) . We conclude that naive B cells expressing GLV H paired with a heterogeneous group of mouse light chains fail to mount significant immune responses to BG505 SOSIP or YU2 SOSIP.
Immune Responses in 3BNC60 MuV H Knockin Mice
Serum from naive MuV H mice has no detectable HIV-1 Env-binding activity in ELISA or neutralizing activity in TZM-bl assays and S4A, and S4B) . To determine whether anti-HIV-1 antibodies can be elicited in these mice, they were immunized three times, with eOD-GT8 60-mer or BG505 SOSIP. The eOD-GT8 60-mer immunization produced strong serologic responses in MuV H mice, but the sera were not cross-reactive against other HIV-1 proteins such as 2cc-core (an engineered gp120 [Dey et al., 2009] ) or YU2 gp140-F, and a fraction of the mice showed CD4bs specificity as measured by ELISA on eOD-GT8 and eOD-GT8 CD4bs knockout (Figures 3A and S4A) . MuV H mice also developed strong serologic responses to BG505 SOSIP, but in contrast to eOD-GT8 immunization, there was serologic crossreactivity to 2cc core, as well as YU2 gp140-F. Moreover, a significant fraction of the response was CD4bs specific as determined by ELISA against YU2 gp140-F and a YU2 gp140-F CD4bs knockout mutant protein ( Figures 3B and S4B ).
To determine whether MuV H mice develop HIV-1 neutralizing responses, we assayed mouse serum on a panel of nine HIV-1 viruses (eight tier 2, and one tier 1) in TZMbl-assays (Li et al., 2005) . We found that the eOD-GT8 60-mer-immunized MuV H (A) Graphs show ELISA results of serum (1/300 dilution) for individual mice against eOD-GT8 (blue) and eOD-GT8 CD4bs knockout (KO, red), 2cc core, and YU2 gp140-F. Naive serum (0) and serum after three (3) immunizations with eOD-GT8 60-mer. (B) As in (A) but after BG505 SOSIP-immunization. ELISA against BG505 SOSIP, 2cc core, and YU2 gp140-F (blue) and YU2 gp140-F CD4bs knockout (KO, red). Lines indicate mean of the group and the colors of the lines correlate to the colors of the dots. (C) Neutralizing activity in TZM-bl assays of serum from individual naive, eOD-GT8 60-mer-or BG505 SOSIP-immunized mice (M) against a panel of HIV-1 viruses. Numbers indicate the reciprocal dilution of serum at the median inhibitory concentration (IC 50 ): red, >1,000; orange, 100-1000; yellow, 50-100, and white, not neutralized at any dilution tested. Gray indicates background activities against the control MuLV virus. See also Figure S4 . mice only showed modest levels of activity mainly against tier 2 Clade D (T247-23) and A (62357.14.D3.3489) viruses that lack glycosylation at position 276 (Genbank: ACD63071 and ABY50658.1, respectively) ( Figure 3C ). In contrast, all seven out of ten BG505 SOSIP-immunized MuV H mice that showed a robust response to BG505 SOSIP in ELISA developed strong neutralizing responses against the autologous Clade A virus. In addition, high levels of neutralization were also evident against T247-23 and 62357.14.D3.3489, and more modest levels of neutralization were seen against three other clade A tier 2 viruses. Finally, four of the seven also showed a low level of neutralizing activity against the clade B tier 2 strain YU2.DG ( Figure 3C ). Thus, BG505 SOSIP trimers elicit potent responses with some cross-clade breadth in MuV H mice, but eOD-GT8 60-mer does not.
eOD-GT8-binding IgG + B cells cannot be detected in naive MuV H mice but increase to 15% and 30% after immunization with eOD-GT8 60-mer or BG505 SOSIP, respectively (Figure S4C) . Thus, both antigens were able to induce clonal expansion and antigen-specific memory B cells. To characterize the antibodies that develop in the MuV H mice, we isolated and cloned the antibodies from antigen-specific memory B cells (Figures S4D and S4E) . As expected, all of the heavy chains obtained carried the MuV H knockin sequence. A total of 138 and 269 light chains were cloned from mice immunized with eOD-GT8 60-mer and BG505 SOSIP, respectively ( Figure 4A and Tables S2 and S4 ). The antibodies obtained from eOD-GT8 60-mer-immunized mice represent 15 independent clones ranging in size from 2 to 24 members; 4 of the clones appeared independently in both eOD-GT8 60-mer-immunized mice. In addition, there were 13 cells that carried unique sequences ( Figure 4A and Table S2 ). In contrast to the antibodies obtained from eOD-GT8 60-merimmunized GLV H mice, the light chains from MuV H immunized mice were highly biased to express 5 aa residue CDRL3s. Moreover, the fourth residue in the CDRL3 was highly selected for an E, which is an important residue in the 3BNC60 antibody and other VRC01 class antibodies. It forms a contact with the backbone of the V5 loop of HIV-1 Env (Scheid et al., 2011; Wu et al., 2010; Zhou et al., 2013) (Figures 4A and 4B and Table S2 ). When assayed by ELISA, the majority of these antibodies were CD4bs specific to eOD-GT8, and a fraction was cross-reactive to YU2 gp140-F ( Figure 4C ). However, despite CD4bs specificity, only two viruses (T247-2 and 62357.14.D3.3489, which lack glycosylation at aa position 276) were neutralized by the monoclonal antibodies tested ( Figure 4D and Table S3 ). Thus, eOD-GT8 60-mer immunization of MuV H mice is highly selective for a subset of mouse light chains with short CDRL3s that allow binding to the CD4bs of eOD-GT8, but this is not sufficient to produce broad neutralizing activity against tier 2 viruses.
Antibodies cloned from BG505 SOSIP-immunized MuV H mice were far more clonally restricted than those obtained after eOD-GT8 60-mer immunization. Light chains were cloned from 269 cells from 3 separate mice, and again, in all cases analyzed, the heavy chain was from the knockin. In contrast to eOD-GT8 60-mer, BG505 SOSIP immunization was dominated by only six highly expanded clones, one of which arose independently in all three mice ( Figure 4A and Table S4 ). Similar to eOD-GT8 60-mer immunization, the B cell clones expanded by BG505 SOSIP immunization were highly biased to express light chains with 5 aa residue CDRL3s that carry the E at the fourth position of CDRL3 ( Figures 4A and 4B and Table S4 ). When tested by ELISA, all but 4 of the 20 antibodies elicited by BG505 SOSIP were CD4bs specific on eOD-GT8, and a fraction of these were cross-reactive to YU2 gp140-F ( Figure 4E ). Finally, some of these monoclonal antibodies showed neutralizing activity against several tier 2 viruses ( Figure 4D and Table S5 ). We conclude that, in contrast to eOD-GT8-, BG505 SOSIP immunization elicits neutralizing antibodies against a diverse group of tier 2 viruses in MuV H mice.
Somatic Mutations
Only the antibodies arising from BG505 SOSIP immunization neutralized tier 2 viruses with an intact glycosylation site at position 276 ( Figure 4D and Tables S3 and S5 ). To gain further insights into this phenomenon, we analyzed the monoclonal antibodies and somatic mutations that arose during the immunization.
The total number of light-chain mutations arising as a result of immunization by the eOD-GT8 60-mer or BG505 SOSIP was similar in both strains of mice, irrespective of whether the knockin heavy chain was germline or mature ( Figure 5A ). In addition, both immunogens selected for B cells bearing the same V L germline gene (V L 10-94*01) carrying similar number of somatic mutations and nearly identical CDRL3s in MuV H mice (Figures  4A and 5B and Tables S2 and S4 ). Thus, the nature of the immunogen did not influence the rate of somatic mutations in the light chains.
However, some mutations in V L 10-94*01-expressing B cells appeared to be specifically selected by immunization with BG505 SOSIP because they were over-represented ( Figure S5A ). For example, Q 90 H was found in the second position of CDRL3 of nearly all members of the V L 10-94 clone obtained independently from three MuV H mice immunized with BG505 SOSIP but rarely in the V L 10-94 clone that arose after immunization with eOD-GT8 60-mer (Figures 4A and S5A and Tables S2 and S4,) , whereas others such as the E mutation found in the fourth residue of CDRL3 were selected by both immunogens ( Figure 4A and Tables S2 and S4 ). Thus, immunization with BG505 SOSIP and eOD-GT8 60-mer led to differential selection of somatically mutated light chains.
To determine whether light chain mutations might be responsible for increasing neutralizing activity after BG505 SOSIP immunization, we produced an antibody that carries the MuV H and the predicted germline light chain of V L 10-94*01 (GL in Figure 5C and Tables S3 and S5 ). When this antibody was compared to BG505 SOSIP-derived monoclonal antibodies, the reverted antibody showed only modest activity. The reverted antibody was similar to the eOD-GT8 60-mer-derived V L 10-94*01 monoclonal antibodies, indicating that only BG505 SOSIP immunization selects for light-chain somatic mutations that increase neutralizing antibody activity in MuV H mice ( Figure 5C ). Moreover, the Q 90 H found in the CDRL3 of nearly all V L 10-94-expressing clones derived from BG505 SOSIP-immunized MuV H mice was sufficient to increase neutralizing activity (Figures 5C  and 5D and Tables S3 and S5 ). Additional mutations that further enhanced or interfered with neutralizing activity appeared randomly ( Figure 5C ). Finally, there was no evidence for selection of specific mutations in the heavy chain in MuV H B cells, as seen by the absence of significant clonal expansion of any particular mutation ( Figure S5B) .
In contrast to the light chains, mutations in the knockin VDJ H sequence were significantly higher in GLV H than in MuV H B cells ( Figures 5E and S5B ), even when comparing Peyer's Patch germinal center B cells in unimmunized mice that are not re- (C) Graphs show ELISA results for individual monoclonal antibodies with the indicated CDRL3s cloned from eOD-GT8 60-mer-immunized MuV H mice against eOD-GT8 (blue) and eOD-GT8 CD4bs knockout (KO, red) (at 0.55 mg/ml) or against YU2 gp140-F (at 5 mg/ml).
(D) Neutralizing activity of a set of representative eOD-GT8 60-mer-or BG505 SOSIP-elicited monoclonal antibodies against 7 HIV-1 tier 2 viruses (1 = MuLV control, 2 = BG505/T 332N, 3 = T247-23, 4 = 62357.14.D3.3489, 5 = Q842.d12, 6 = 3365.V2.c30, 7 = YU2.DG, and 8 = 0815.v3.c3) compared to the serum of the mouse they were cloned from. Colors for monoclonal antibodies indicate concentration of monoclonal antibody at the median inhibitory concentration (IC 50 ): orange, 0.1 to 1 mg/ml; yellow, 1 to 10 mg/ml; green, 10-25 or 50 mg/ml and white, not neutralized at any concentration tested. Lowest dilution tested for serum was 1:50, highest concentration tested for monoclonal antibodies were between 10 and 50 mg/ml (see Tables S3 and S5) . X indicates sample not tested. The numbering of the antibodies corresponds to the numbering of the antibodies in Tables S3 and S5 . Colors and numbering for serum as in Figure 3C . (E) Graphs show ELISA results for individual monoclonal antibodies with the indicated CDRL3s cloned from BG505 SOSIP-immunized MuV H mice against eOD-GT8 (blue) and eOD-GT8 CD4bs knockout (KO, red) (at 0.55 mg/ml) or against YU2 gp140-F (at 5 mg/ml). For ELISA graphs, lines indicate mean of the group, and the colors of the lines correlate to the colors of the dots. See also Figure S4 and Tables  S2, S3 , S4, and S5.
sponding to injected antigens ( Figure 5F ). However, the mutation rate in the germline intron downstream of J H 4, which is contiguous to the VDJ H , was similar in the two mouse strains ( Figure 5G ). We conclude that the somatic mutation machinery is equally active in the two knockin B cell types, but the highly mutated MuV H is less susceptible to mutation than its unmutated GLV H counterpart.
DISCUSSION
Immunoglobulin knockin mice such as GLV H and MuV H provide a unique opportunity to examine the effects of specific immunogens and trace the evolution of an anti-HIV-1 antibody starting from predicted germline or from a synthetic intermediate composed of a mutated human heavy V region chain and a mouse germline light chain. The B cells in these mice show reduced repertoire diversity because the heavy chain is fixed; nevertheless, the light chains are free to recombine randomly, and the resulting B cell repertoire contains only very rare cells that bind to the HIV-1 immunogens tested.
Immunization revealed that B cells bearing predicted germline antibodies only responded to antigens specifically designed to bind to these antibodies and not to more native-appearing HIV-1 Env trimers. This result is consistent with the observation that the germline version of 3BNC60 and related antibodies fail to bind to nearly all tested recombinant HIV-1 Env antigens and supports the idea that specifically designed antigens will be required to elicit B cells bearing these antibodies (Hoot et al., 2013; Jardine et al., 2013; McGuire et al., 2013) . Nevertheless, it remains possible that a more diverse repertoire of light chains would include a rare pairing that might be triggered by a more native-like trimer.
One of the objectives of immunization with a germline-targeting antigen is to expand and further diversify rare clones of B cells that can serve as precursors of bNAbs. For 3BNC60 and related CD4bs antibodies, this would require selection of B cells expressing antibodies with short CDRL3s and somatic hypermutation in germinal centers. Although rare in the pre-immune repertoire, GLV H B cells expressing antibodies with short CDRL3s were enriched after immunization with the eOD-GT8 60-mer, providing proof of concept for selection of germline precursors of this class of antibodies by germline targeting antigens. In contrast, both the engineered eOD GT8 and the native-like BG505 SOSIP trimer elicited antigen-specific B cell responses in mice bearing MuV H . However, only BG505 SOSIP produced a significant neutralizing response.
Both types of antigens selected rare MuV H B cells expressing light chains with short CDRL3s and both induced similar levels of somatic hypermutation. It would be interesting to determine .1 mg/ml; orange, 0.1 to 1 mg/ml; yellow, 1 to 10 mg/ml; green, 10-25 or 50 mg/ml and white, not neutralized at any concentration tested. X indicates sample not tested (see also Tables S3 and  S5 ). Position of aa mutations in the LCs compared to germline is highlighted in red. (D) Graph shows neutralization score for V L 10-94*01 cloned antibodies with Q 90 Q or Q 90 H CDRL3 from immunized MuV H mice. Neutralization score: sum of viruses tested IC 50 0.1-1 mg/ml: 3, 1-10 mg/ml: 2, 10-50 mg/ml: 1, and >50 mg/ml: 0. (E) Somatic hypermutations in individual heavychain (HC) sequences obtained after eOD-GT8 60-mer or BG505 SOSIP immunization in GLV H or MuV H mice. Data in (A), (B), and (E) are pooled from 9 mice (M#1, 2, 3, 4, 7, 9, 16, 17, and 18). Figure S5 and Tables S3 and S5. whether these cells would also be selected when competing with a complete repertoire of B cells in a wild-type C57Bl6 mouse. Nevertheless, the responses to the immunogens differed in two important ways, each of which likely contributed to the eventual selection of tier 2 neutralizing antibodies to HIV-1 by the BG505 SOSIP trimer. First, the repertoire of light chains that was selected to undergo clonal expansion by the trimer was far more restricted than for the eOD-GT8 60-mer. This restriction is likely to be related to the glycan at position 276 that enforces the relatively narrow geometry of the recessed CD4 binding pocket in the trimer Kwong et al., 1998; Lyumkis et al., 2013) . Under physiologic conditions, this cavity accommodates the single terminal Ig-like domain in CD4. Significant alterations, including somatic mutations, deletions, or insertions, must be made for the bulkier paired heavy-and light-chain Ig domains in 3BNC60 and related antibodies to access the CD4bs . Many of these alterations are already present in the heavy chain of MuV H B cells, facilitating extensive contacts with gp120 . Nevertheless, the steric restrictions imposed by the glycan at 276 in BG505 SOSIP limit the number of different light chains that can be recruited into the immune response against the trimer. In contrast, eOD-GT8 was designed to be a more open structure that is missing the glycan at position 276 and can accommodate germline antibodies. It therefore recruits a more diverse but overlapping set of antibodies in mice bearing the MuV H , none of which has significant breadth against tier 2 viruses in TZM-bl assays. Our work was limited to BG505 SOSIP as a model for a native-appearing antigen, and it remains possible that other antigens with similar steric restrictions would be equally efficient in selecting neutralizing antibodies.
The second difference between the two immunogens was in their ability to select for IgV L mutations that enhance breadth and potency. In particular, the Q 90 H mutation in the CDRL3 of the V L 10-94 light chains that are selected in the BG505 SOSIP immunized mice may aid in rigidifying the light chain contacts to the CD4bs. Structural modeling of the V L 10-94 light chain indicates that the histidine side chain, unlike the glutamine side chain, can adopt a commonly observed, low-energy conformation that also makes stabilizing interactions within the light chain ( Figure S5C ). The planar packing with Y 91 , the close proximity to the N276 glycan, a hydrogen bond with CDRL1, and a potential for interacting with a gp120-bridging water molecule may help preconfigure the antibody for engagement of the CD4bs. The modeling and neutralization data indicate that the mutation could cause structural changes that influence binding to gp120 and may be necessary for the activity of the BG505 SOSIP elicited antibodies ( Figure S5C ).
Although only a small number of the mutations are likely to be crucial for breadth and potency, achieving the right combination of aa substitutions by random mutagenesis is a low probability event. Finding that the mature, fully mutated 3BNC60 V H suffers fewer mutations after immunization than the predicted germline 3BNC60 despite equal rates of somatic mutation in the light chains and in the J H 4 intron suggests that the sequence of the V H is an important determinant of its susceptibility to hypermutation. Consistent with this idea, the fully mutated 3BNC60 V H has many fewer AID target sites than the predicted germline V H (Betz et al., 1993; Longerich et al., 2006; Neuberger et al., 1998) . RGYW/WRCY are preferred targets for somatic hypermutation: 9 out of 12 RGYW and 7 out of 8 WRCY motifs found in GLV H sequence are missing in MuV H ( Figure S5D ).
HIV-1 and SHIV infection can be prevented by passive infusion of potent bNAbs into mice or macaques, but despite significant efforts, including large clinical trials, all attempts to elicit such antibodies in humans by immunization have failed to date (Klein et al., 2013; Mascola and Haynes, 2013; West et al., 2014) . Antibody cloning experiments revealed that these bNAbs differ from most other antibodies in that they are significantly more mutated, leading to the suggestion that eliciting them would require immunization with a sequential series of different antigens selected or designed to shepherd the antibody response through several successive rounds of mutation and selection in germinal centers (Klein et al., 2013; Mouquet et al., 2010; Scheid et al., 2009) . Consistent with this notion, elegant studies of human HIV-1 infection show a correlation between HIV-1 viral evolution and the antibody response (Doria-Rose et al., 2014; Liao et al., 2013; Wu et al., 2015) . Our experiments demonstrate that specific immunogens are required to target B cells at different stages of evolution of the anti-HIV-1 neutralizing response and lend support to the idea that vaccination for HIV-1 will require a strategy that involves sequential immunization with different antigens.
EXPERIMENTAL PROCEDURES
Mice and Immunizations Knockin mice were produced by gene targeting using the human VDJ H sequences of the mature and germline 3BNC60 heavy chain (Hoot et al., 2013) . The targeting vector was designed with homologous regions flanking the endogenous J segments, which results in the deletion of the J segments and thereby minimizes rearrangement of the wild-type locus (Pelanda et al., 1997; Shih et al., 2002) . Mice were immunized once every 2 weeks with 10 mg of protein in Alum Imject (Thermo Scientific). Serum was collected 2 weeks after each immunization. All experiments were performed according to the protocols approved by the IACUC at Rockefeller University.
Protein Production eOD-GT8 is an improved version of eOD-GT6 (Jardine et al., , 2015 . The eOD-GT8 CD4bs knockout carries mutations to reintroduce the N276 glycan and also includes D368R and N279A. eOD-GT8 60-mer for immunization and monomers for ELISA detection were produced as previously described . The 426c.TM 4 DV1-3 immunogen (with or without AviTag) is a derivative of the 426c.NLGS. TMDV1-3 (McGuire et al., 2014) with the following additional modifications: D276N, S278R, and G471S (HXB2 numbering). The protein was produced as previously described (McGuire et al., 2014) . Multimerized 426c.TM 4 DV1-3 was generated as follows: Avitagged and biotinylated 426c.TM 4 DV1-3 was mixed with streptavidin and biotinylated dextran (Life Technologies) at a 3:1 ratio of Env to biotin, with the assumption that the biotin had 77 biotin molecules/dextran. Streptavidin (New England Biolabs) was added to achieve a 3:1:1 Env to streptavidin to biotin ratio. To generate YU2 SOSIP.664, a gene encoding YU2 SOSIP.664 was constructed to include the ''SOS'' substitutions (A501C gp120 and T605C gp41 ), the ''IP'' substitution (I559P gp41 ), changing the gp120-gp41 cleavage site to 6R (REKR to RRRRRR) and introducing a stop codon after residue 664 gp41 (HXB2 numbering) analogous to mutations introduced to generate BG505 SOSIP.664 as described . YU2 SOSIP.664, BG505 SOSIP.664, and B41 SOSIP.664 (referred to as YU2 SOSIP, BG505 SOSIP, and B41 SOSIP) were produced and purified by the 2G12/SEC method as previously described (Chung et al., 2014; Pugach et al., 2015; Sanders et al., 2013) . YU2 gp140-F CD4bs knockout is a YU2 gp140-foldon (F) HIV-1 Env with A281T and D368K mutations, and proteins were produced as previously described (Forsell et al., 2008) .
ELISA ELISA for eOD-GT8, eOD-GT8 CD4bs knock-out, YU2 gp140-F, YU2 gp140-F knock-out, YU2 SOSIP, and B41 SOSIP was performed by coating high binding 96-well plates (Corning Incorporated) with 200 ng/well of protein.
After incubation overnight (ON) at 4 C, the plates were washed in wash buffer (PBS with 0.05% TWEEN 20 [Sigma] ) and incubated in blocking buffer (PBS with 2% milk). Serum samples or monoclonal antibodies were added in dilutions. Plates were washed and secondary antibody, HRP conjugated anti-mouse or anti-human IgG (Jackson Immuno Research), was added. Plates were developed by the addition of HRP substrate (Life Technologies), and the absorbance was measured at 405 nm. ELISA specific for BG505 SOSIP was performed using the D7324-capture ELISA as described in Sanders et al. (2013) .
TZM-bl Neutralization Assay
Serum samples and monoclonal antibodies were tested for neutralization against a panel of selected HIV-1 pseudoviruses using a TZM-bl neutralization assay as previously described (Li et al., 2005) .
B Cell Enrichment
B cells were enriched from single-cell suspensions of total splenocytes prior to flow cytometry staining by magnetic bead separation using anti-CD19 or anti-CD43 MicroBeads (Miltenyi Biotec). The separation was performed on MACS separation LS columns according to the manufacturer's instructions.
Flow Cytometry
Single-cell suspensions of total splenocytes, enriched B cells, or BM were stained with different combinations of the following antibodies: anti-CD4 APC-eFluor 780, anti-CD8 APC-eFluor 780, anti-Gr1 APC-eFluor 780, anti-F4/80 APC-eFluor 780, anti-B220 APC, anti-B220 APC-eFluor 780, anti-B220 FITC, anti-CD19 PeCy7, anti-CD38 Alexa Fluor 700, anti-CD93 APC, anti-IgM PerCP-eFluor 710, anti-CD21/CD35 eFluor 450 and anti-GL7 eFluor 660 (eBiosciences), anti-CD23 PE (BioLegend), anti-CD4 PE-CF594, anti-CD8 PE-CF594, anti-Ly-6G and Ly-6C PE-CF594, anti-IgG1 and CD95 BV421 (BD Biosciences). Live dead aqua stain was added to separate dead cells (Life Technologies), and eOD-GT8-specific cells were visualized by the addition of FITC-conjugated eOD-GT8 and PE-conjugated eOD-GT8 CD4bs knockout. BG505 SOSIP- (Sok et al., 2014) and 2cc-specific memory B cells were visualized by the addition of biotinylated protein with the addition of streptavidin-conjugated PE and APC, respectively (BD Biosicences).
B Cell Sorting
Staining and single-cell sorting of naive and memory B cells was performed as follows: for naive mice, CD4-, CD8-, Gr-1-, F4/80-, B220+, and IgM+ B cells were sorted. For immunized mice, CD4-, CD8-, Gr-1-, F4/80-, B220+, CD38-, IgM-, IgG+, eOD-GT8 CD4bs knockout and eOD-GT8+ or CD4-, CD8-, Gr-1-, F4/80-, B220+, CD38-, IgM-, IgG+, BG505 SOSIP+, and 2cc+ memory B cells were single-cell sorted into 96-well plates using a FACSAria III sorter (Becton Dickinson). The cells were lysed with 4 ml lysis buffer containing RNASin (Promega) 40 U/ml (0,3 ml), DPBS (Dulbecco) 103 (0.2 ml), DTT (Invitrogen) 100 mM (0.4 ml), and nuclease-free water (3.1 ml). The sorted plates were stored at À80 C until further processing (Tiller et al., 2009 ). Sequencing and cloning primers are listed in Table S6 . Antibodies were cloned using a modified sequence and ligation-independent cloning (SLIC) approach as described in Li and Elledge (2007) . Antibodies were produced in HEK293-6E cells as previously described . Bulk sorted GC B cells were amplified with the following primers: pF: GGGATGGTCATGTATCATCCTTTTTCTAG TAGC and p279: TCCTAGGAACCAACTTAAGAGT.
Structural Modeling
To create a structural model of one of the antibodies elicited in the MuV H mouse by BG505 SOSIP, we integrated information from HIV bNAb structures and mouse light-chain structures. The antibody 3BNC117 has very high sequence similarity to 3BNC60 (ten mutations in heavy chain and three mutations in light chain [Scheid et al., 2011] ) and has a co-crystal structure available (PDB: 4JPV). We made an initial model of 3BNC60 by running 50 ROSETTA-Fixbb (Leaver-Fay et al., 2011) simulations to model the mutations from the 3BNC117 structure. The elicited antibodies contain a mutated mouse light chain from the V L 10-94*01 germline gene; here, we focused on the Q 90 H mutation. To model the light chain, we used an unrelated crystal structure of a mouse V L 10-94*01 antibody (PDB: 1EMT). We superimposed the mouse antibody to the 3BNC60 model and created a hybrid of 3BNC60-mature heavy chain and V L 10-94*01 light chain to mimic what was elicited in MuV H . The 1EMT structure did not contain a five aa CDRL3, so we aligned the light chain from 3BNC117 and grafted the five amino CDRL3 onto our model. The final model was obtained by adding an interfacial water molecule (as found in the structurally similar VRC-CH31 light chain; PDB: 4LSP) and by running 100 ROSETTA-Relax simulations to allow for slight movements of the backbone.
Statistical Analysis
Statistical differences were analyzed by the Mann-Whitney test. GraphPad Prism software was used for analysis, and data were considered significant at *p % 0.05, **p % 0.01, and ***p % 0.001. 
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